CBIO
CRESCENT BIOPHARMA, INC.Company Information
- Company Name
- CRESCENT BIOPHARMA, INC.
- CIK
- CIK0001253689
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CBIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-16
- Last sale
- 2026-09-18
- Shares purchased (TTM)
- 2,213,450
- Shares sold (TTM)
- 82,541
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 28,888,519
- Shares outstanding
- 27,756,044
- Ownership
- 104.08%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- 14.18%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | 1 | 1 | 10 | 1 | 2 | - | 0 | - | - | - | - | - | ||||||
| Related Party | 1 | 1 | 10 | 1 | 2 | - | 0 | 15 | - | - | - | - | ||||||
| Series Seed Convertible Preferred Stock | - | - | 0 | 0 | -20 | 20 | 0 | 0 | - | - | - | - | ||||||
| Series A Preferred Stock | - | - | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Other Assets | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 172 | 189 | 213 | 133 | 153 | 22 | 35 | 14 | 22 | 31 | 42 | 49 | ||||||
| Cash | - | - | - | - | 153 | - | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 0 | 0 | 18 | - | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 7 | 6 | 5 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | ||||||
| Assets Current | 179 | 196 | 237 | 135 | 154 | 6 | 35 | 16 | 24 | 33 | 44 | 52 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 1 | 0 | ||||||
| Security Deposit | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 0 | - | 0 | - | - | - | - | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 2 | 2 | - | 0 | - | 0 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Accrued Liabilities Current | - | - | 16 | - | - | 3 | 2 | 3 | 3 | 4 | 5 | 5 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | - | - | ||||||
| Assets | 183 | 199 | 240 | 138 | 157 | 6 | 36 | 16 | 24 | 34 | 45 | 53 | ||||||
| Accounts Payable Current | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Contract With Customer Liability Current | 3 | 3 | 4 | - | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Liabilities Current | 19 | 14 | 36 | 20 | 17 | 3 | 10 | 4 | 4 | 5 | 7 | 6 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | - | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities | 20 | 15 | 37 | 22 | 18 | 3 | 47 | 4 | 4 | 5 | 7 | 7 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 4 | 4 | - | - | - | - | - | - | - | - | - | - | ||||||
Temporary Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 379 | 375 | 371 | 192 | 190 | 500 | 2 | 498 | 497 | 496 | 495 | 494 | ||||||
| Retained Earnings Accumulated Deficit | -220 | -195 | -172 | -79 | -55 | -497 | -18 | -487 | -477 | -467 | -456 | -447 | ||||||
| Stockholders Equity | 163 | 184 | 203 | 117 | 139 | -30 | -15 | 0 | 20 | 29 | 38 | 47 | ||||||
| Liabilities And Stockholders Equity | 183 | 199 | 240 | 138 | 157 | 6 | 36 | 16 | 24 | 34 | 45 | 53 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | - | - | - | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 175 | 175 | 175 | 175 | 175 | 150 | 40 | 150 | 150 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 28 | 28 | 28 | 14 | 14 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 28 | 28 | 28 | 14 | 14 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Long Term Notes Payable | - | - | 0 | 0 | 0 | - | 37 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCRESCENT BIOPHARMA, INC. (CBIO) — SEC Financial Statements & Analysis
CRESCENT BIOPHARMA, INC. (CBIO) is a pharmaceutical preparations company, incorporated in E9. CRESCENT BIOPHARMA, INC. trades on Nasdaq as: CBIO. CRESCENT BIOPHARMA, INC. (CBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, CRESCENT BIOPHARMA, INC. carries a market cap of $499.61M, a P/E ratio of -3.03x, a P/B ratio of 3.06x, a P/S ratio of 480.86x, an enterprise value of $327.91M, and an EV/EBITDA multiple of -1.95x. On profitability, it posts an operating margin of -16214.73%, a net margin of -15892.59%, a Return on Equity (ROE) of -109.17%, a Return on Assets (ROA) of -97.08%, and a Return on Invested Capital (ROIC) of -791.29%. Per share, it reports EPS of $-5.95, diluted EPS of $-60.02, free cash flow per share of $-2.65, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 201.29% year-over-year, and EPS growth of 50.80% year-over-year. On the balance sheet, it maintains a current ratio of 9.66x, a quick ratio of 9.26x, working capital of $160.47M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, an interest coverage ratio of -152.04x, free cash flow of $-73.62M (TTM), and net debt of $-171.70M. Figures sourced from SEC EDGAR.
- Market Cap
- $499.61M
- P/E TTM
- -3.03x
- EPS TTM
- $-5.95
- P/B TTM
- 3.06x
- ROE TTM
- -109.17%
- ROA TTM
- -97.08%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-73.62M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CRESCENT BIOPHARMA, INC. in?
CRESCENT BIOPHARMA, INC. (CBIO) operates in the Pharmaceutical Preparations industry.
What exchange does CBIO trade on?
CRESCENT BIOPHARMA, INC. (CBIO) trades on the Nasdaq.
Where is CRESCENT BIOPHARMA, INC. incorporated?
CRESCENT BIOPHARMA, INC. is incorporated in Cayman Islands.
When was CRESCENT BIOPHARMA, INC. (CBIO)'s most recent SEC filing?
CRESCENT BIOPHARMA, INC. (CBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is CBIO's market cap?
CRESCENT BIOPHARMA, INC. (CBIO) has a market capitalization of $499.61M as of 2026-06-30.
What is CBIO's EPS (earnings per share)?
CRESCENT BIOPHARMA, INC. (CBIO)'s trailing twelve month EPS is $-5.95 as of 2026-06-30.
What is CBIO's ROE (return on equity)?
CRESCENT BIOPHARMA, INC. (CBIO)'s trailing twelve month Return on Equity (ROE) is -109.17% as of 2026-06-30.
What is CBIO's ROA (return on assets)?
CRESCENT BIOPHARMA, INC. (CBIO)'s trailing twelve month Return on Assets (ROA) is -97.08% as of 2026-06-30.
What is CBIO's ROIC (return on invested capital)?
CRESCENT BIOPHARMA, INC. (CBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -791.29% as of 2024-09-30.
What is CBIO's EV/EBITDA?
CRESCENT BIOPHARMA, INC. (CBIO)'s trailing twelve month EV/EBITDA is -1.95x as of 2026-06-30.